The MarketReader Minute
💊 Biotech Faces Pressure Amid Gilead Hold and Retail Sales Miss, Verve Therapeutics Jumps on Eli Lilly Acquisition | Biotech Sector Insights
Biotech stocks declined today as broader market weakness and a drop in U.S. retail sales added pressure to an already cautious sector tone. Gilead fell after the FDA placed a clinical hold on its HIV trials, while analysts trimmed outlooks on Vertex.